MTOR and non-small cell lung carcinoma: We discovered that (ruxolitinib + afatinib) treatment reduced mTOR phosphorylation at both S2448 and S2481 in multiple breast and lung cancer cell lines, including the NSCLC PDX isolate ADOR, arguing that our drug combination was inactivating both the mTORC1 and mTORC2 signaling complexes (Figure 4A).